We retrospectively analyzed the prognostic impact of proteasome subunit beta type 1 rs12717 polymorphism in 211 consecutively diagnosed multiple myeloma cases. Patients carrying the variant G allele showed significantly shorter progression-free survival. In proteasomes of individuals with G/G genotype, we found significantly reduced protease activity and lower inhibitory capacity of bortezomib on the caspase-and trypsin-like activity. Background: Proteasome subunit beta type 1 (PSMB1) rs12717 polymorphism, a single nucleotide polymorphism with unknown functional effect, was recently reported to influence response to bortezomib-based therapy in follicular lymphoma. Patients and Methods: We retrospectively analyzed the prognostic impact of this polymorphism in 211 consecutively diagnosed multiple myeloma cases, and performed in vitro experiments to look into its functional consequences. Results: On univariate analysis, patients carrying the variant G allele showed significantly shorter progression-free survival (PFS) with a pattern suggestive of a gene-dose effect (PFS 26.4, 22.3, and 16 .4 months in C/C, C/G, and G/G patients, respectively, P ¼ .002). On multivariate analysis, carrying the G/G genotype was a significant independent risk factor for relapse (hazard ratio [HR] 2.29, P < .001) with a similar trend in C/G carriers (HR 1.33, P ¼ .097) when compared with the major allele carrier C/C cohort. Our subsequent in vitro analyses demonstrated significantly reduced protease activity in proteasomes of individuals with G/G genotype compared with that of C/C carriers, despite that PSMB1 expression and proteasome assembly remained unaltered. Bortezomib exhibited a lower inhibitory capacity on the caspase-and trypsin-like activity of proteasomes from G/G individuals. Conclusion: Our results show that carriership of PSMB1 rs12717 minor allele is predictive for suboptimal response with bortezomib treatment, which could be explained by less active proteasomes that are less sensitive to bortezomib, and myeloma cells consequently relying on other escape mechanisms to cope with the abundance of misfolded proteins.
Introduction
Proteasome inhibitors (PIs) have a fundamental role in the treatment of multiple myeloma (MM). Bortezomib, the first in class PI received accelerated approval from the U.S. Food and Drug Administration (FDA) in relapsed refractory MM in 2003, and entered into phase 3 trials in first-line setting. [1] [2] [3] Bortezomib-based combinations are currently standard upfront treatments for MM in most countries, and second-generation PIs are increasingly used following the FDA and subsequent European Medicines Agency approval of carfilzomib and ixazomib. Proteasomes are multienzyme complexes providing a pathway for the degradation of poly-ubiquitinated intracellular proteins, thereby eliminating misfolded or unfolded proteins, as well as key regulators of important cellular processes, including cell-cycle progression, DNA repair, apoptosis, immune response, signal transduction, transcription, metabolism, and developmental programs. 4, 5 The 26S proteasome, a large 2.4-MDa ATP-dependent proteolytic complex located in both the cytoplasm and the nucleus, consists of a 20S core catalytic cylindrical complex capped at both ends by 19S regulatory subunits. 6 The core structure is composed of 4 axially stacked rings of nonidentical subunits: 2 alpha rings each composed of 7 nonidentical alpha subunits (a1-7, encoded by PSMA1-7) and 2 beta rings each formed by 7 nonidentical beta subunits (b1-7, encoded by PSMB1-7).
7 Three b subunits (b5, b2, and b1) are located on the inner surface of the proteolytic chamber and are responsible for chymotrypsin-like, trypsin-like, and post-glutamyl peptide hydrolyzing (caspase-like) activities, respectively. 8 Other b subunits are essential for the formation and stability of the proteolytic environment on the inner surface of the heptameric rings. 4 The exact role of these subunits, however, is yet to be characterized. It has also been reported that they have potential roles in regulating the assembly and stability of the ring, and in addition PSMB1 (coding for b6 subunit)
has a potential role as a transcriptional activator. 9, 10 High proteasome activity has been reported in different malignancies. 11 In malignant plasma cells that exhibit extremely active protein synthesis, proteasomes along with chaperones, such as heat shock proteins, play a critical role in cellular homeostasis. This might explain the therapeutic window of PI treatment in MM and the additional effect of heat shock protein inhibitors combined with PIs. 12 Bortezomib binds to the b5 subunit, but also interacts with other subunits of proteasome, such as the b1 subunit. 13 Some of the new-generation PIs, such as marizomib, inhibit all 3 proteolytic activities. Although PSMB5 variants have been identified previously in preclinical models of bortezomib resistance, they were not detected in relapsed/refractory patients' tumor samples, suggesting alternative mechanisms behind bortezomib resistance.
14 Proteasome subunit beta type 1 (PSMB1) rs12717 single nucleotide polymorphism (c.31C>G substitution resulting in p.Pro11Ala amino acid change) was recently reported to be associated with greater clinical benefit in patients with relapsed follicular lymphoma treated with a bortezomib-containing combination. 15 Our hypothesis was that PSMB1 P11A polymorphism could affect the function of proteasomes and therefore have an impact on the prognosis of myeloma, especially in patients treated with PI-based regimens. To the best of our knowledge, the functional consequence of PSMB1 P11A polymorphism has not been tested in MM, apart from a single study with a limited number of patients showing no statistically significant association between genotype and survival. 14 
Patients and Methods
Patients, Clinical Data, Treatment, and Response Criteria
We analyzed the association of PSMB1 P11A polymorphism and treatment outcome of 211 patients consecutively diagnosed with myeloma having had first-line chemotherapy at the St László Hospital, Budapest, Hungary, between January 2007 and November 2013. International scoring system (ISS) and fluorescence in situ hybridization (FISH) status were established at diagnosis; FISH testing was performed on bone marrow slides using probes for chromosome 13q and 17p deletion, translocation (11;14) , (4;14) , (14;16) , and 1q amplification. FISH results were available in 194 of the 211 patients. For the purpose of this study, patients with t(4;14), t(14;16), 1q amplification, and del(17p) were grouped together as high risk. Previous studies have shown that del(13q) in patients lacking t(4;14) and del(17p) was no longer of prognostic significance. 16, 17 The treatment decision was the discretion of the treating physician; treatment continued until best response and then the patients who were eligible for transplantation received a high-dose cyclophosphamide-primed stem cell mobilization, followed by high-dose melphalan-conditioned autologous stem cell transplantation (ASCT 18 Response was formally assessed at the end of the treatment, or following transplantation in the case of patients receiving ASCT. During their follow-up, patients were reviewed regularly every 2 to 3 months until disease progression or death. The median follow-up was 40 months. The study was approved by the Hungarian National Ethics Committee, and participants signed informed consents.
Genotyping
Genomic DNA was isolated from bone marrow or peripheral blood. PSMB1 P11A polymorphism was tested using LightCycler 480II (Roche Diagnostics, Basel, Switzerland) melting curve analysis. 
Flow Cytometry Analysis of Proteasomes and PSMB1 Expression
For in vitro characterization of proteasome expression and function, healthy volunteers previously genotyped as either PSMB1 major variant C/C or homozygous G/G minor variant (3 men and 4 women, mean age: 42 AE 8 years) were investigated. EDTA anticoagulated whole blood samples were fixed with 1% paraformaldehyde (37 C, 5 minutes), spun down (500g, 5 minutes),
washed with phosphate-buffered saline (PBS), and sonicated (10 seconds, 37 kHz, 50/100W 
Assessment of Proteasome Functions
For studying proteasome function, peripheral blood mononuclear cells were isolated by density gradient separation (1200g, 20 minutes; Leucoprep Lymphocyte Separation Media; Intron Biotechnology, Seoul, South Korea), washed 3 times with saline solution, and lysed with a buffer containing 40 mM Tris, 50 mM NaCl, 5 mM MgCl 2 , 2 mM b-mercaptoethanol, and 10% glycerol. After sonication and removal of cell debris, the total protein concentration was assessed by Bradford assay, and adjusted to 2.5 mg/mL. The chymotrypsin-like, caspase-like, and trypsin-like activities of the lysates were determined by Proteasome Activity Fluorometric Assay Kit II (UBPBio) according to the manufacturer's instructions.
Briefly, 120 mL assay buffer containing the fluorogenic peptide substrate was added to 30 mL of the lysates. For studying bortezomib inhibition, the samples were preincubated with the drug (room temperature, 30 minutes) before the start of the reaction. The generation of fluorescent product (460 nm) was assessed by a fluorescence plate reader at 360-nm excitation. The specific activities were calculated from the initial slopes of the kinetic curves and the protein content of the samples.
Statistical Methods

Comparisons of dichotomous variables were performed by
Pearson c 2 test or Fisher exact test, as appropriate; continuous variables were compared with Kruskal-Wallis or Mann-Whitney tests. Log-rank test was performed to compare PFS and OS. Following univariate analysis, variables with P values < .05 in the entire cohort were included in the multivariate analysis. Using the stepwise selection procedure for all of the variables of interest (sex, age, ISS, FISH, ASCT, bortezomib treatment, immunoglobulin, lactate dehydrogenase), the Cox proportional hazard model was used for multivariate analysis of OS and PFS. The few missing ISS and FISH values were replaced using random imputation. Adjusted hazard ratios (HRs), 95% confidence interval (CI) values, and tests for interaction were computed. For the comparison of PSMB1 expression, proteasome assembly, and function in the different subgroups, Student t test was used after testing for the normality and homogeneity of variances. P < .05 was considered as significant difference. The analyses were carried out using the SPSS (version 20.0; SPSS, Chicago, IL) software package.
Results
Study Population
Patient characteristics are shown in Table 1 . Among the 211 consecutive patients newly diagnosed with MM, 105 were men and 106 were women, and the median age was 64 (28-84) years. Most had either IgG (57.3%) or IgA (19.9%) myeloma, and 21.8% had light chain and 0.9% nonsecretory disease. ISS was calculated in each case at diagnosis, with 25.8%, 24.4%, and 49.8% of the patients being in ISS groups 1, 2, and 3, respectively. As the clinical behavior of the ISS 1 and 2 groups was similar, these 2 cohorts were merged. According to our predefined FISH risk stratification, 31.4% of the patients were allocated into the high-risk and 68.6% into the low-risk group.
A total of 154 patients (77 men and 77 women; median age 61.5 years) received bortezomib-based treatment, and 57 (28 men and 29 women; median age 68 (48-84) years, P for age < .001) had other, nonebortezomib-containing protocols.
Within the bortezomib-treated group, 83 transplant-eligible patients were treated with bortezomib-thalidomide-dexamethasone (VTD), 19 whereas melphalan-prednisolone-bortezomib (MPV), 20 the standard therapy for older patients, was applied in 45 cases. Twenty other patients had bortezomib-doxorubicin-dexamethasone (PAD) 21 and 6 bortezomib-dexamethasone (VD) 2 chemotherapy.
Other, nonebortezomib-containing protocols were applied as follows: cyclophosphamide-thalidomide-dexamethasone, 22 vincristinedoxorubicin-dexamethasone (VAD), 23 lenalidomide-dexamethasone, 24 and melphalan-prednisolone (MP); the numbers and genotype distribution in these subcohorts are summarized in Table 1 . Of the bortezomib-treated patients, 59.1% had first-line ASCT, whereas the ASCT frequency was lower, 35.1%, in the nonbortezomib group, reflecting the fact that from 2007 in our center, VTD became the preferred induction in transplant candidates, whereas oral protocols remained more feasible for frailer patients. The median age of the first-line transplanted and nonefirst-line transplanted patients was 58 (range, 28-70) and 72 (range, 39-84) years, respectively (P < .001). There was no significant difference in the distribution of disease characteristics, prognostic markers, and applied treatment between the various PSMB1 genotype groups (Table 1) .
PSMB1 Allele Frequencies
Genotype distribution in our patient cohort was as follows: 84 patients (39.8%) had homozygous C/C, 95 patients (45%) heterozygous C/G, and 32 patients (15.2%) G/G genotype, similar to that published previously.
14 The minor allele frequency (37.7% AE 4.7%) in patients with MM was not different from the reported allele frequency for Caucasian reference population (40.4% AE 7.0%) in the 1000 Genome Project or (34.8%-46.0%) in the National Center for Biotechnology Information dbSNP databases.
25
PSMB1 Genotype and Response to Treatment
Four patients had no disease reassessment because of early death. Within the whole cohort, 41.2%, 19.4%, and 30.8% of the patients PSMB1 P11A Polymorphism in Myeloma had CR, VGPR, and PR, respectively, and 6.6% exhibited NR. Slightly more patients had a CR in the C/C genotype group (48.8%) as compared with the G/C and G/G groups (35.8% and 37.5%, respectively), but this difference was not significant (P ¼ .189) Apart from this, there were no associations between the response levels and the genotype groups neither in the whole cohort, nor in subgroups according to ISS, FISH, or chemotherapy type (data not shown).
There was no difference in the numbers of chemotherapy cycles required to reach the best response in the 3 genotype subgroups. Approximately half of the patients had ASCT consolidation, and the proportion of patients having ASCT was not different among the 3 genotype groups.
PSMB1 Genotype and Univariate Analysis of Survival
The median PFS and OS of the whole group were 23.4 (20.7-26.1) and 55.7 (49.6-61.8) months, respectively. The known predictors (age, ASCT, ISS, FISH) all had significant impacts on survival.
Analyzing the 3 PSMB1 genotype groups, the PFS was 26. (Figure 1 ). In Cox proportional hazards modeling, carrying 2 G alleles increased the chance of relapse by 2.14 (1.39-3.29; P ¼ .001) with a trend in carriers of a single G allele (HR 1.36 [0.98-1.89], P ¼ .067), whereas no statistically significant difference was seen in the OS of the subgroups.
PSMB1 Genotype and Multivariate Analysis of Survival
In multivariate analysis, besides age, ISS, FISH, bortezomib treatment, and ASCT, G/G genotype was also a significant risk factor for shorter PFS. Homozygous G/G patients had a shorter PFS compared with C/C genotype patients with an HR of 2.29 
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(1.46-1.36) (P < .001) ( Table 2) , whereas heterozygous C/G patients showed a trend of worse prognosis with an HR of 1.33 (0.95-1.86) (P ¼ .097). Regarding OS, a significant difference between the C/C and C/G genotypes was found, but not in the comparison of the C/C and G/G genotypes (Table 2) . Statistical interaction testing did not show significant interactions of PSMB1 genotype and either bortezomib treatment (P ¼ .092 for G/G vs. C/C, and P ¼ .63 for C/G vs. C/C regarding PFS) or ASCT (P ¼ .420); however, revealed interaction of PSMB1 with FISH risk status regarding PFS (P ¼ .044) and with ISS regarding OS (P ¼ .022).
Subgroup Analyses
In the PFS and OS of the ISS-and FISH-stratified subgroups, we found the same pattern as in the whole study population, with significant differences among the C/C, C/G, and G/G genotype groups both in the ISS 1 and 2 and the ISS 3 and standard risk FISH subgroups, but not in the FISH high-risk group (Table 3) . 
PSMB1 P11A Polymorphism in Myeloma
The PSMB1 genotype mattered the most in bortezomib-treated patients, where it has a highly significant effect in the bortezomib-treated cohort ( Figure 1B , Table 3 ).
Assessment of Functional Consequence of the PSMB1 Polymorphism
To investigate the possible molecular mechanism of how the P11A (c.31C>G) polymorphism in PSMB1 may influence the proteasome assembly and/or function, first the number of proteasomes (Figure 2A ) and the expression level of PSMB1 ( Figure 2B ) were determined in peripheral white blood cells obtained from healthy individuals with C/C or G/G genotype. No difference between the 2 subgroups was found in proteasome levels or PSMB1 expression (Figure 2A and B) . Similarly, no difference was observed when these 2 parameters were assessed specifically in various types of nucleated peripheral blood cell types; that is, monocytes, T cells, B cells, and granulocytes (Figure 2A and B) .
Following this, the protease activities of proteasomes of C/C and G/G genotype carrier subgroups were analyzed and found that chymotrypsin-, trypsin-, and caspase-like activities were all significantly lower in the G/G subgroup, indicating selective reduction of the proteasome function in individuals carrying the G/G polymorphism ( Figure 2C) .
We also studied the in vitro inhibitory effect of bortezomib on the chymotrypsin-, trypsin-, and caspase-like activities of the proteasomes, and found a threefold difference between half the inhibitory concentration (IC 50 ) values of bortezomib inhibition of the caspaselike activity of proteasomes of healthy subjects with G/G and C/C genotypes (2.05 vs. 6.07 mM). More profound difference, 1 order of magnitude shift was seen in the IC 50 values, when the trypsin-like activities were blocked by bortezomib (44.4 vs. 462 mM) ( Figure 2D ).
Discussion
Our results confirm that PSMB1 P11A polymorphism has a significant impact on the survival of patients with myeloma. We originally hypothesized that this polymorphism might interact with bortezomib treatment, given its mechanism of action, but we could not demonstrate statistical interaction between bortezomib exposure and PSMB1 genotype; however, this could be the result of the smaller number of patients in the nonebortezomib-treated group.
The literature of PSMB1 P11A polymorphism is sparse. A study compared the outcome of relapsed patients with follicular 
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Clinical Lymphoma, Myeloma & Leukemia November 2017 -739 lymphoma treated with rituximab in combination with or without bortezomib. It was reported that one biomarker pair (ie, PSMB1 P11A G allele carriers with low CD68 expression) was associated with a significant PFS benefit, when these patients were treated with the combination of bortezomib and rituximab as compared with those having received rituximab as monotherapy. 
PSMB1 P11A Polymorphism in Myeloma
Another study analyzed the sequence of b-subunit genes of the 20S proteasome in patients with relapsed MM using samples from patients who participated in the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib versus high-dose dexamethasone. No statistically significant interaction between the PSMB1 P11A and time-to-progression or OS was found; however, this particular subanalysis included only 23 patients and still, there was a marginal association (P ¼ .077). This report concluded that because of the limited size of their dataset, additional studies are required to further evaluate this single nucleotide polymorphism in MM. 14 In Cox modeling of PFS, the risk of relapse increased in the presence of 1 G allele and then increased further with the second, which finding could suggest the presence of a gene-dose effect; however, currently there are no published data on the functional consequence of the PSMB1 P11A polymorphism. Therefore, we investigated whether this polymorphism influences the assembly, the functions, and the inhibitability of proteasomes using peripheral blood cells of healthy individuals. In addition to the fact that the availability of plasma cell of patients with MM is rather limited, these cells most likely carry a high number of somatic mutations, which can cause such a statistical noise that may hamper the analysis of proteasome activities. Alternatively, myeloma cell lines could be used. However, cell line pairs with the same genetic background possessing G/G or C/C genotype for the PSMB1 gene are not available thus far.
The protein encoded by PSMB1 is the b6 subunit, 1 of the 2 times 7 elements of the inner proteolytic chamber of the proteasome. This subunit has no known direct proteolytic activity, but has been proposed to contribute to the assembly and stability of the 2 heptameric beta rings of proteasomes, establishing the proteolytic environment on their inner surface. Our findings, that proteasomes with G/G PSMB1 genotype exhibit lower peptidase activities and lower sensitivity to bortezomib in terms of the caspase-like and trypsin-like activities, are in line with this proposed model, and suggest an indirect interaction with the proteasome function. Our experiments clearly demonstrated that this polymorphism is not neutral; however, further studies are required to elucidate the exact molecular mechanism of how the polymorphism in PSMB1 leads to reduced activity and changes in bortezomib-sensitivity of proteasomes. Nevertheless, we can speculate that to maintain appropriate cellular homeostasis, these cells compensate for the reduced proteasome proteolytic activities with increased activities in the alternative degradative mechanisms, which ultimately may lead to reduced susceptibility to proteasome inhibition as observed in cells homozygous for the P11A polymorphism ( Figure 2D ). This concept may especially apply to cell types with intense protein synthesis and secretion; for example, plasma cells, in which the proteolytic burden is grossly increased. Bortezomib is thought to drive cells to programmed cell death by inhibiting the proteasomal degradation of unfolded proteins, thereby overwhelming the degradation capacity of the cell and triggering the unfolded protein response. 26, 27 This may help explain why bortezomib has an apparent potentiating effect when given as cotherapy with 17-AAG, a heat shock protein 90 inhibitor in patients with relapsed or refractory MM. 12 With regard to another component of the proteasome complex, namely PSMA5, it has been reported that low plasma levels are associated with longer PFS in mantle cell lymphoma treated with bortezomib. 28 In addition, recent data showed that silencing individual proteasome genes, including PSMA5 and PSMB2/3/7, sensitized MM cells to bortezomib. 29, 30 However, similar data in connection with PSMB1 are not reported thus far.
Conclusion
PSMB1 P11A is a novel predictive marker in MM, which could help to identify patients with a probability of having a suboptimal response to bortezomib who might benefit from alternative management, which could potentially include the inhibition of heat shock proteins.
Clinical Practice Points
PSMB1 P11A polymorphism results in decreased protease activity of proteasomes and reduced inhibitory effect of bortezomib on their activity. Patients with myeloma carrying the variant allele of the PSMB1 P11A polymorphism have a significantly shorter PFS. Based on this, PSMB1 P11A is a new predictive marker that could help to identify patients who could benefit from alternative management.
